The Pan-deacetylase Inhibitor Panobinostat Modulates the Expression of Epithelial-mesenchymal Transition Markers in Hepatocellular Carcinoma Models

Overview

Journal Oncol Lett

Specialty Oncology

Date 2012 Dec 21

PMID 23255907

Citations 15

Authors

Pietro Di Fazio

Roberta Montalbano

Karl Quint

Beate Alinger

Ralf Kemmerling

Tobias Kiesslich

Matthias Ocker

Daniel Neureiter

Affiliations

Soon will be listed here.

Abstract

Deacetylase inhibitors (DACis) represent a novel therapeutic option for human cancers by classically affecting proliferation or apoptosis. Since transdifferentiation and dedifferentiation play a key role in carcinogenesis, we investigated the epigenetic influence on the molecular differentiation status in human hepatocellular carcinoma (HCC) models. Markers of differentiation, including cytokeratin (Ck) 7, Ck8, Ck18, Ck19, Ck20, vimentin, sonic hedgehog homolog (SHH), smoothened (Smo), patched (Ptc), glioma-associated oncogene homolog 1 (Gli1), CD133, octamer-binding transcription factor 4 (Oct4) and β-catenin, were examined in the human HCC cell lines HepG2 and Hep3B in vitro and in vivo (xenograft model) using quantitative real-time PCR and immunohistochemistry following treatment with the pan-DACi panobinostat (LBH589). Compared to untreated controls, treated HepG2 xenografts, and to a lesser extent cell lines, demonstrated a significant increase of differentiation markers Ck7 and Ck19 (classical cholangiocellular type) and Ck8 and Ck18 (classical HCC type), and a decreased level of dedifferentiation markers vimentin (mesenchymal) and SHH/Ptc (embryonic), paralleled with a more membranous expression of β-catenin. These findings were dose-dependently correlated with tumor size, necrosis rate, microvessel density and mitosis/Ki-67-associated proliferation rate. Our results demonstrate that the differentiation status of human HCC cells is influenced by the pan-DACi panobinostat, indicating that this treatment may influence the epithelial-mesenchymal transition (EMT) status related to metastasis and aggressiveness.

Citing Articles

Pharmacological inhibition of LSD1 suppresses growth of hepatocellular carcinoma by inducing GADD45B.

Sang N, Zhong X, Gou K, Liu H, Xu J, Zhou Y MedComm (2020). 2023; 4(3):e269.

PMID: 37250145 PMC: 10209615. DOI: 10.1002/mco2.269.

Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition.

Tao S, Liang S, Zeng T, Yin D Front Immunol. 2023; 13:1043667.

PMID: 36685594 PMC: 9845774. DOI: 10.3389/fimmu.2022.1043667.

Regulation of epithelial-mesenchymal transition by protein lysine acetylation.

Kong F, Ma L, Wang X, You H, Zheng K, Tang R Cell Commun Signal. 2022; 20(1):57.

PMID: 35484625 PMC: 9052664. DOI: 10.1186/s12964-022-00870-y.

Emerging Advances in Combinatorial Treatments of Epigenetically Altered Pediatric High-Grade H3K27M Gliomas.

Leszczynska K, Jayaprakash C, Kaminska B, Mieczkowski J Front Genet. 2021; 12:742561.

PMID: 34646308 PMC: 8503186. DOI: 10.3389/fgene.2021.742561.

Prominent Role of Histone Modifications in the Regulation of Tumor Metastasis.

Markouli M, Strepkos D, Basdra E, Papavassiliou A, Piperi C Int J Mol Sci. 2021; 22(5).

PMID: 33803458 PMC: 7967218. DOI: 10.3390/ijms22052778.

References

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Miller C, Singh M, Rivera-Del Valle N, Manton C, Chandra J . Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J Biomed Biotechnol. 2011; 2011:514261. PMC: 3134392. DOI: 10.1155/2011/514261. View

J van t Veer L, Dai H, van de Vijver M, He Y, Hart A, Mao M . Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(6871):530-6. DOI: 10.1038/415530a. View

Kiesslich T, Alinger B, Wolkersdorfer G, Ocker M, Neureiter D, Berr F . Active Wnt signalling is associated with low differentiation and high proliferation in human biliary tract cancer in vitro and in vivo and is sensitive to pharmacological inhibition. Int J Oncol. 2009; 36(1):49-58. View

Todaro M, Francipane M, Medema J, Stassi G . Colon cancer stem cells: promise of targeted therapy. Gastroenterology. 2010; 138(6):2151-62. DOI: 10.1053/j.gastro.2009.12.063. View

Atadja P . Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett. 2009; 280(2):233-41. DOI: 10.1016/j.canlet.2009.02.019. View

Eguchi G, Kodama R . Transdifferentiation. Curr Opin Cell Biol. 1993; 5(6):1023-8. DOI: 10.1016/0955-0674(93)90087-7. View

Ellis L, Atadja P, Johnstone R . Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther. 2009; 8(6):1409-20. DOI: 10.1158/1535-7163.MCT-08-0860. View

Goteri G, Olivieri A, Ranaldi R, Lucesole M, Filosa A, Capretti R . Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients outcome. Int J Immunopathol Pharmacol. 2006; 19(2):421-31. DOI: 10.1177/039463200601900218. View

10.

Wachter J, Neureiter D, Alinger B, Pichler M, Fuereder J, Oberdanner C . Influence of five potential anticancer drugs on wnt pathway and cell survival in human biliary tract cancer cells. Int J Biol Sci. 2012; 8(1):15-29. PMC: 3226029. DOI: 10.7150/ijbs.8.15. View

11.

Na D, Lee J, Yoo J, Oh B, Choi G, Park Y . Invasion and EMT-associated genes are up-regulated in B viral hepatocellular carcinoma with high expression of CD133-human and cell culture study. Exp Mol Pathol. 2010; 90(1):66-73. DOI: 10.1016/j.yexmp.2010.10.003. View

12.

Moll R, Divo M, Langbein L . The human keratins: biology and pathology. Histochem Cell Biol. 2008; 129(6):705-33. PMC: 2386534. DOI: 10.1007/s00418-008-0435-6. View

13.

Neureiter D, Zopf S, Leu T, Dietze O, Hauser-Kronberger C, Hahn E . Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models. Scand J Gastroenterol. 2006; 42(1):103-16. DOI: 10.1080/00365520600874198. View

14.

Rountree C, Mishra L, Willenbring H . Stem cells in liver diseases and cancer: recent advances on the path to new therapies. Hepatology. 2011; 55(1):298-306. PMC: 3245372. DOI: 10.1002/hep.24762. View

15.

Jana S, Paliwal J . Apoptosis: potential therapeutic targets for new drug discovery. Curr Med Chem. 2007; 14(22):2369-79. DOI: 10.2174/092986707781745569. View

16.

Jones P, Taylor S, Wilson V . DNA modification, differentiation, and transformation. J Exp Zool. 1983; 228(2):287-95. DOI: 10.1002/jez.1402280212. View

17.

Schrader J, Gordon-Walker T, Aucott R, van Deemter M, Quaas A, Walsh S . Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells. Hepatology. 2011; 53(4):1192-205. PMC: 3076070. DOI: 10.1002/hep.24108. View

18.

Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y, Villanueva A . Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol. 2012; 56(6):1343-50. PMC: 3355195. DOI: 10.1016/j.jhep.2012.01.009. View

19.

Sabbah M, Emami S, Redeuilh G, Julien S, Prevost G, Zimber A . Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Updat. 2008; 11(4-5):123-51. DOI: 10.1016/j.drup.2008.07.001. View

20.

Kiesslich T, Neureiter D, Alinger B, Jansky G, Berlanda J, Mkrtchyan V . Uptake and phototoxicity of meso-tetrahydroxyphenyl chlorine are highly variable in human biliary tract cancer cell lines and correlate with markers of differentiation and proliferation. Photochem Photobiol Sci. 2010; 9(5):734-43. DOI: 10.1039/b9pp00201d. View